her2阳性转移性乳腺癌患者曲妥珠单抗治疗中断与生存之间的关系：一项回顾性研究

IF 1.9 4区医学 Q3 INFECTIOUS DISEASES

Journal of Chemotherapy Pub Date : 2025-04-02 DOI:10.1080/1120009X.2025.2485520

Ludmila Andrade Alves Ferreira, Mário Jorge Sobreira da Silva, Patricia Ribeiro Portella de Araújo, Maely Peçanha Fávero Retto

{"title":"her2阳性转移性乳腺癌患者曲妥珠单抗治疗中断与生存之间的关系：一项回顾性研究","authors":"Ludmila Andrade Alves Ferreira, Mário Jorge Sobreira da Silva, Patricia Ribeiro Portella de Araújo, Maely Peçanha Fávero Retto","doi":"10.1080/1120009X.2025.2485520","DOIUrl":null,"url":null,"abstract":"This retrospective study analyzed the effect of trastuzumab treatment interruption on overall survival (OS) and progression-free survival (PFS) within two years after diagnosis in women with HER2-positive metastatic breast cancer. Sociodemographic, clinicopathological, and therapeutic variables were collected from medical records of patients diagnosed between 2013 and 2017 at a comprehensive cancer care center in Brazil. Survival estimates were performed using the Kaplan-Meier method and the log-rank test. The Cox Regression model was used to estimate the risk of outcomes. The average OS was 20.2 months, and the PFS was 13.1 months. Interruption of trastuzumab treatment was associated with an increase in overall survival time compared with continued treatment (22.5 months; 95% CI: 21.8 - 23.3 vs. 17.7 months; 95% CI: 15.9 - 19.4; P = 0.001). The adjusted risk model revealed that continued trastuzumab therapy was independently associated with a 2.86-fold increased risk of mortality.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association between trastuzumab treatment interruption and survival in HER2-positive metastatic breast cancer patients: a retrospective study.\",\"authors\":\"Ludmila Andrade Alves Ferreira, Mário Jorge Sobreira da Silva, Patricia Ribeiro Portella de Araújo, Maely Peçanha Fávero Retto\",\"doi\":\"10.1080/1120009X.2025.2485520\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This retrospective study analyzed the effect of trastuzumab treatment interruption on overall survival (OS) and progression-free survival (PFS) within two years after diagnosis in women with HER2-positive metastatic breast cancer. Sociodemographic, clinicopathological, and therapeutic variables were collected from medical records of patients diagnosed between 2013 and 2017 at a comprehensive cancer care center in Brazil. Survival estimates were performed using the Kaplan-Meier method and the log-rank test. The Cox Regression model was used to estimate the risk of outcomes. The average OS was 20.2 months, and the PFS was 13.1 months. Interruption of trastuzumab treatment was associated with an increase in overall survival time compared with continued treatment (22.5 months; 95% CI: 21.8 - 23.3 vs. 17.7 months; 95% CI: 15.9 - 19.4; P = 0.001). The adjusted risk model revealed that continued trastuzumab therapy was independently associated with a 2.86-fold increased risk of mortality.\",\"PeriodicalId\":15338,\"journal\":{\"name\":\"Journal of Chemotherapy\",\"volume\":\" \",\"pages\":\"1-10\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-04-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1120009X.2025.2485520\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2485520","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

这项回顾性研究分析了曲妥珠单抗治疗中断对her2阳性转移性乳腺癌女性诊断后两年内总生存期（OS）和无进展生存期（PFS）的影响。从巴西一家综合癌症护理中心2013年至2017年诊断的患者的医疗记录中收集了社会人口学、临床病理学和治疗变量。生存估计采用Kaplan-Meier法和log-rank检验。采用Cox回归模型估计结果风险。平均OS为20.2个月，PFS为13.1个月。与继续治疗相比，曲妥珠单抗治疗的中断与总生存时间的增加相关(22.5个月；95% CI: 21.8 - 23.3 vs. 17.7个月；95% ci: 15.9 - 19.4；p = 0.001)。调整后的风险模型显示，继续曲妥珠单抗治疗与死亡风险增加2.86倍独立相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Association between trastuzumab treatment interruption and survival in HER2-positive metastatic breast cancer patients: a retrospective study.

This retrospective study analyzed the effect of trastuzumab treatment interruption on overall survival (OS) and progression-free survival (PFS) within two years after diagnosis in women with HER2-positive metastatic breast cancer. Sociodemographic, clinicopathological, and therapeutic variables were collected from medical records of patients diagnosed between 2013 and 2017 at a comprehensive cancer care center in Brazil. Survival estimates were performed using the Kaplan-Meier method and the log-rank test. The Cox Regression model was used to estimate the risk of outcomes. The average OS was 20.2 months, and the PFS was 13.1 months. Interruption of trastuzumab treatment was associated with an increase in overall survival time compared with continued treatment (22.5 months; 95% CI: 21.8 - 23.3 vs. 17.7 months; 95% CI: 15.9 - 19.4; P = 0.001). The adjusted risk model revealed that continued trastuzumab therapy was independently associated with a 2.86-fold increased risk of mortality.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Chemotherapy 医学-药学

CiteScore

3.70

自引率

0.00%

发文量

144

审稿时长

6-12 weeks

期刊介绍： The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy. The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs. Specific areas of focus include, but are not limited to: · Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents; · Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy; · Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents; · The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs; · Drug interactions in single or combined applications; · Drug resistance to antimicrobial and anticancer drugs; · Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research; · Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs; · Pharmacogenetics and pharmacogenomics; · Precision medicine in infectious disease therapy and in cancer therapy; · Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.